Pharmacokinetics of new oral anticoagulants: implications for use in routine care

References

• FDA approved betrixaban for the prophylaxis of venous thromboembolism (VTE) in adult patients [internet]. 2017 [cited 2018 Aug 27]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm
   Google Scholar
• Refusal of the marketing authorisation for Dexxience (betrixaban): outcome of re-examination [internet]. 2018 [cited 2018 Aug 27]. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004309/WC500246331.pdf
   Google Scholar
• Di Pasquale G, Proto C, Riva L. Fibrillazione atriale e nuovi anticoagulanti: rivoluzione terapeutica? G Ital Cardiol. 2013;14:69–75.
   Google Scholar
• Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41–46.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:339–354.
   Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in patients with atrial fibrillation. New England J Med. 2013;369:2093–2104. [cited 2018 Aug 27]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Lip GYH, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: the prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8:S12–20.
   PubMed Web of Science ®Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med [Internet]. 2013;368:1272–1274. [cited 2018 Aug 27]. Available from: http://www.nejm.org/doi/10.1056/NEJMp1302834
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264–2273.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Bmj [Internet]. 2016;i3189. [cited 2018 Aug 27]. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.i3189
   Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2014;131:157–164.
   PubMed Web of Science ®Google Scholar
• Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19:3961–3967.
   PubMed Web of Science ®Google Scholar
• Pelliccia F, Tanzilli G, Schiariti M, et al. I nuovi anticoagulanti orali nel mondo reale : il valore aggiunto dei dati dei registri e degli studi osservazionali. Focus su apixaban. 2016;17:3–21.
   Google Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. Thromb Haemost. 2016;115:939–949.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–1153.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation - The RELIEF study. Int J Cardiol [Internet]. 2016;203:882–884. [cited 2018 Aug 27].
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047–2053.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:1–18.
   Web of Science ®Google Scholar
• Blann AD, Banerjee A, Lane DA, et al. Net clinical benefit of edoxaban versus no treatment in a “real world” atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Int J Cardiol [Internet]. Available from. 2015;201:693–698. [cited 2018 Aug 27].
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Caleb Alexander G, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5:1–12.
   Web of Science ®Google Scholar
• Ferri N, Corsini A. Nuovi anticoagulanti orali: considerazioni di farmacologia clinica. G Ital Cardiol. 2015;16:3S–16S.
   Web of Science ®Google Scholar
• Brighton T. Experimental and clinical pharmacology: new oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33:38–41.
   Web of Science ®Google Scholar
• Horn JR. HPD. Dabigatran: A new oral anticoagulant [internet]. 2010 [cited 2018 Aug 27]. Available from: http://www.pharmacytimes.com/publications/issue/2010/december2010/druginteractions-1210
   Google Scholar
• Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–469S.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2017;38:2137–2149.
   PubMed Web of Science ®Google Scholar
• Regione Lombardia. Interazioni TAO, AVK e NAO, progetto FarmAmico.
   Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (80-). 2009;323:1718–1722.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Northup A, Johnson D, et al. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy. 2016;36:e5–7.
   PubMed Web of Science ®Google Scholar
• Hager N, Bolt J, Albers L, et al. Development of left atrial thrombus after coadministration of dabigatran etexilate and phenytoin. Can J Cardiol [Internet]. Available from. 2017;33:554.e13-554.e14. [cited 2018 Aug 27].
   PubMedGoogle Scholar
• Serra W, Li Calzi M, Coruzzi P. Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation. Clin Pract [Internet]. 2015;5:63–64. [cited 2018 Aug 27]. Available from: http://www.clinicsandpractice.org/index.php/cp/article/view/788
   Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs [Internet]. 2009;9:59–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19178132
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, et al. Absence of clinically relevant interactions between rivaroxaban — an oral, direct factor xa inhibitor — and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40(5):1688-707.
   Google Scholar
• Nardi F, Gulizia MM, Colivicchi F, et al. Position paper ANMCO: I nuovi anticoagulanti orali nella prevenzione del tromboembolismo nella fibrillazione atriale: scenari clinici e prospettive future. G Ital Cardiol. 2016;17:3S–28S.
   Google Scholar
• Kreutz R, Haas S, Holberg G, et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81:724–734.
   PubMed Web of Science ®Google Scholar
• Reber G., Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59.
   PubMedGoogle Scholar
• Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother. 2014;48:1258–1268.
   PubMed Web of Science ®Google Scholar
• Bauer A, Limperger V, Nowak-Göttl U. End-stage renal disease and thrombophilia. Hamostaseologie [Internet]. 2015;36:103–107. [cited 2018 Apr 20]. Available from: http://www.schattauer.de/index.php?id=1214&doi=10.5482/HAMO-14-11-0063
   PubMed Web of Science ®Google Scholar
• Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888–2899.
   PubMed Web of Science ®Google Scholar
• Harel Z, Mamdani M, Juurlink DN, et al. Novel oral anticoagulants and the risk of major hemorrhage in elderly patients with chronic kidney disease: a nested case-control study. Can J Cardiol. 2016;32:986.e17-986.e22.
   Web of Science ®Google Scholar
• Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2018.
   PubMed Web of Science ®Google Scholar
• Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, et al. Comparative safety and efficacy of apixaban versus warfarin in patients with end stage renal disease: Meta-analysis Pacing Clin Electrophysiol. 2018 May 23.
   Google Scholar
• Andò G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis. Int J Cardiol [Internet]. 2017;231:162–169. [cited 2018 Aug 27].
   PubMed Web of Science ®Google Scholar
• Sardar P, Chatterjee S, Herzog E, et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol [Internet]. 2014;30:888–897. [cited 2018 Aug 27].
   PubMed Web of Science ®Google Scholar
• John Camm A, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non–vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779–2790.
   PubMed Web of Science ®Google Scholar
• Sadlon AH, Tsakiris DA, Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions. Swiss Med Wkly [Internet]. 146:w14356. [cited 2018 Aug 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27683276
   Google Scholar
• Xu Y, Kus T, Greiss I, et al. The impact of body weight on adverse outcomes with novel oral anticoagulants and Warfarin: preliminary results from the integrate study. J Am Coll Cardiol [Internet]. 2016;67:798. [cited 2018 Aug 27]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109716307999
   Web of Science ®Google Scholar
• Castellucci LA, Shaw J, Van Der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res [Internet]. 2015 [cited 2018 Aug 27];136:727–731.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC: a cohort study. Thromb Haemost. 2016;115:31–39.
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6:567–574.
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin [Internet]. 2014;30:2461–2469. [cited 2018 Aug 27]. Available from: http://www.tandfonline.com/doi/full/10.1185/03007995.2014.933577
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients - Results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17:530–538.
   PubMed Web of Science ®Google Scholar
• Al-Khalili F, Lindström CBL, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin [Internet]. 2016 [cited 2018 Aug 27]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26765366
   PubMed Web of Science ®Google Scholar
• Cemin R, Di Pasquale G, Colonna P, et al. Dieci quesiti in attesa di risposta sull’utilizzo dei nuovi anticoagulanti orali nella fibrillazione atriale. G Ital Cardiol. 2016;17:884–896.
   Google Scholar
• Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med [Internet]. 2012;366:1287–1297. [cited 2018 Aug 27] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22449293
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11:1295–1299.
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjøth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13:495–504.
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration. Am Heart J [Internet]. 2014 [cited 2018 Aug 27];167:810–817.
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin [Internet]. 2015;31:1889–1895. [cited 2018 Aug 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26211815
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin [Internet]. 2015;31:2167–2173. [cited 2018 Aug 27]. Available from: http://www.tandfonline.com/doi/full/10.1185/03007995.2015.1096242
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm [Internet]. 2016;22:1319–1329. [cited 2018 Aug 27]. Available from: http://www.jmcp.org/doi/10.18553/jmcp.2016.22.11.1319
   PubMedGoogle Scholar
• Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83:2096–2106.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi SKotecha D, Esc guidelines for the management of atrial fibrillation developed in collaboration with eacts. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (London, England) [Internet]. 200610;367:1903–1912. [cited 2018 Aug 27] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16765759
   PubMed Web of Science ®Google Scholar
• Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–1193.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio-Thoracic Surg [Internet]. 2017:213–254. [cited 2018 Aug 27]. Available from: http://academic.oup.com/ejcts/article/doi/10.1093/ejcts/ezx334/4095091/2017-ESC-focused-update-on-dual-antiplatelet
   Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DLOldgren J, Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524.
   PubMed Web of Science ®Google Scholar
• Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119:1363–1369.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet (London, England) [Internet]. 2015 Jun 6;385:2288–2295. [cited 2018 Aug 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25769361
   PubMed Web of Science ®Google Scholar
• Terrovitis JV, Ntalianis A, Kapelios CJ, et al. Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Hell J Cardiol. 2015;56:20–25.
   PubMed Web of Science ®Google Scholar
• Fernández de Velasco Pérez D. [Dabigatran versus warfarin in patients with mechanical heart valves]. Rev Clin Esp [Internet]. 2014 May [cited 2018 Aug 27];214:221. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24895742
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Li JS, Manlhiot C, et al. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease. Circulation [Internet]. 2014;130(14):1192–1203. [cited 2018 Aug 27]. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.113.008428
   PubMed Web of Science ®Google Scholar
• Young G. New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res [Internet]. 2011 [cited 2018 Aug 27];127:70–74.
   PubMed Web of Science ®Google Scholar
• Drews T, Stiller B, Hübler M, et al. Coagulation management in pediatric mechanical circulatory support. ASAIO J. 2007;53:640–645. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17885339
   PubMed Web of Science ®Google Scholar
• Corrao S, Argano C, Nobili A, et al. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. Eur J Intern Med [Internet]. 2015;26:243–249. [cited 2018 Aug 27].
   PubMed Web of Science ®Google Scholar